PARP1 and cancer: Hence, combination treatment consisting of EGFR, cMET, and PARP1 inhibitors posits a novel therapeutic strategy in cancer treatment involving overexpression of PARP1/EGFR/cMET, which are frequent alterations in most solid tumors [132].